Astrazeneca Plc $AZN Shares Sold by Montrusco Bolton Investments Inc.

Posted by Geri Gentry on Oct 13th, 2026

Montrusco Bolton Investments Inc. decreased its position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 19.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 176,054 shares of the company’s stock after selling 42,009 shares during the quarter. Montrusco Bolton Investments Inc.’s holdings in Astrazeneca were worth $28,720,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Madson Wealth Advisors Inc increased its position in Astrazeneca by 3.9% during the third quarter. Madson Wealth Advisors Inc now owns 3,344 shares of the company’s stock worth $540,000 after buying an additional 126 shares during the period. Sax Wealth Advisors LLC lifted its stake in Astrazeneca by 37.6% in the third quarter. Sax Wealth Advisors LLC now owns 2,036 shares of the company’s stock valued at $329,000 after buying an additional 556 shares during the last quarter. NorthCrest Asset Manangement LLC boosted its holdings in shares of Astrazeneca by 7.4% in the third quarter. NorthCrest Asset Manangement LLC now owns 4,020 shares of the company’s stock valued at $638,000 after acquiring an additional 276 shares during the period. Avior Wealth Management LLC acquired a new stake in shares of Astrazeneca in the third quarter valued at approximately $321,000. Finally, Vertrix Wealth Management LLC grew its position in shares of Astrazeneca by 18.3% during the third quarter. Vertrix Wealth Management LLC now owns 3,945 shares of the company’s stock worth $637,000 after acquiring an additional 611 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Bank of America reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Deutsche Bank Aktiengesellschaft upgraded shares of Astrazeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, September 15th. Nordea Equity Research upgraded shares of Astrazeneca from a “sell” rating to a “buy” rating in a research note on Tuesday. CICC Research began coverage on shares of Astrazeneca in a research report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price objective on the stock. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Fifteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $206.67.

Get Our Latest Stock Report on AZN

Astrazeneca Stock Performance

Shares of NYSE:AZN traded down $2.40 during trading on Tuesday, reaching $155.93. The company had a trading volume of 3,112,378 shares, compared to its average volume of 2,800,521. Astrazeneca Plc has a fifty-two week low of $153.41 and a fifty-two week high of $212.71. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67. The stock’s fifty day moving average price is $161.94 and its 200 day moving average price is $176.75. The firm has a market capitalization of $241.84 billion, a price-to-earnings ratio of 23.31, a price-to-earnings-growth ratio of 1.35 and a beta of 0.27.

Astrazeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings results on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%. The firm had revenue of $15.38 billion during the quarter, compared to the consensus estimate of $15.44 billion. During the same period last year, the company earned $2.17 earnings per share. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. As a group, equities research analysts predict that Astrazeneca Plc will post 9.36 EPS for the current year.

Trending Headlines about Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

Positive Sentiment: Higher FY2026 earnings estimate: Erste Group Bank raised its FY2026 EPS forecast for AstraZeneca to $10.45 from $10.34, well above the broader consensus estimate of $9.36. The revision suggests improving confidence in the company’s earnings outlook. Erste Group Bank raises AstraZeneca FY2026 EPS estimate
Positive Sentiment: Efzimfotase alfa could become a significant growth driver: Citi maintained its “buy” rating and £186 price target after Phase III HICKORY data for AstraZeneca’s rare-disease therapy. Citi estimates peak sales could reach approximately $4.4 billion—nearly twice its current base case—if the drug receives broad approval for adult patients with hypophosphatasia in the United States. AstraZeneca efzimfotase alfa sales potential
Neutral Sentiment: ASBMR presentation provides additional pipeline information: AstraZeneca presented efzimfotase alfa data at the 2026 American Society for Bone and Mineral Research meeting. The presentation supports investor interest in the program, but commercial value remains dependent on regulatory approval, labeling and eventual market adoption. AstraZeneca ASBMR 2026 presentation transcript
Neutral Sentiment: Broker sentiment remains constructive: Wall Street brokerages rate AstraZeneca “Moderate Buy,” while a comparison with Vanda Pharmaceuticals does not introduce a material new company-specific catalyst. AstraZeneca Moderate Buy rating

Astrazeneca Company Profile

(Free Report)

AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, United Kingdom. Its research, development and commercial operations focus on prescription medicines for serious and chronic diseases, with an emphasis on discovering and delivering innovative therapies rather than operating as a diversified healthcare conglomerate.

The company’s principal therapeutic areas include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunological conditions; and rare diseases.